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The time course of degradation of a radiolabelled natural ceramide has been studied in Intact, living lymphold cells and skin fibroblasts from normal 
individuals and from patients affected with Farber disease, an inborn disorder of ceramlde metabolism due to deficient activity of lysosomal 
ceramidase. The hydrolysis of ceramide m lysosomes was selectively followed by examining the turnover of an LDL-associated radioactlve 
sphmgomyelin. This permitted to estimate accurately the effective lysosomal ceramidase activity and to demonstrate: (1) a very active catabohsm 
of ceramlde m normal cells; and (il) the absence of a complete block of ceramide degradation in Farber cells. The possible Implication of ceramlde 
as a hpld mediator of the pathogenesis of Farber disease is discussed 
Ceramide; Lysosome; Farber disease; Ceramldase: Sphmgomyehn: Lipid targetting 
1. INTRODUCTION 
Ceramide (N-acylsphingosine) is a key intermediate 
in the synthesis and degradation of sphingomyelin 
(SPM), gangliosides and other glycolipids, i.e. mem- 
brane, lipoprotein and myelin constituents [ 1,2]. Little 
is known about the physiological role of ceramide. Due 
to its high concentration in the stratum corneum [3,4], 
it may account for the preservation of water impermea- 
bility of the skin [5]. Recently, ceramide and its meta- 
bolic products have been suggested as very potent bio- 
logical effecters [6&S]. In particular, the pivotal partici- 
pation of ceramide in an intracellular signal transduc- 
tion pathway which implicates SPM degradation has 
been proposed in various cellular events as differentia- 
tion [9,10], proliferation [l l] or apoptosis [13]. 
The hydrolysis of ceramide is catalyzed by cerami- 
dases (N-acylsphingosine deacylases: EC 3.5.1.23). 
Three ceramidases have been distinguished based on 
their pH optima, substrate specificity, tissue distribu- 
tion and subcellular localization [I 3-201. Of these, only 
the lysosomal ceramidase exhibits a deficient activity in 
Farber disease [21]. This rare, inherited lipid storage 
disorder, also called lipogranulomatosis, is associated 
with accumulation of ceramide in the patient tissues and 
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is clinically characterized by painful swelling of joints, 
subcutaneous nodules and a hoarse cry [22]. 
As for other sphingolipidoses, the mechanisms under- 
lying the pathophysiology of Farber disease are not yet 
clarified. One may postulate that, if ceramide has indeed 
key regulatory second messenger functions, the absence 
of its degradation might lead to fatal lesions. Since the 
effective lysosomal ceramidase activity in intact living 
cells has never been reported, the aim of the present 
study was to estimate accurately this activity in order 
to appreciate the possible role of the lysosomal storage 
of ceramide as a lipid mediator of the pathogenesis of 
Farber disease. Intact cells were incubated with the im- 
mediate radiolabelled precursor of ceramide, SPM 
which was associated to human LDL to ensure specific 
targetting of the sphingolipid to the lysosomes and se- 
lective determination of the lysosomal ceramidase activ- 
ity. 
2. MATERIALS AND METHODS 
2.1. Chenucals und radrolabrlled hprds 
[‘HlSphingomyelin ([‘HISPM, 400 mCi/mmol) was obtained from 
CEA (Gif-sur-Yvette. France) by catalytic tritiatlon of bovine brain 
SPM (Sigma), the sphmgolipid was purified by preparative TLC, using 
chloroform/methanol/water (100:42:6, v/v) as developmg solvent. The 
purity of the radIoactive SPM was further checked by analytical TLC 
and corresponded to 97-990/C Acidic hydrolysis showed that the SPM 
was radiolabelled on both the sphmgoid base and fatty acid moieties, 
m which the radiolabel represented 45 and 55%, respectively. [9.10- 
‘H]Oleic acid (10 Ci/mmol) was from DuPont NEN (Les Ulis. 
France). Standard radiolabelled ceraxmde was synthesized by con- 
densing [‘Hloleic acid and sphingosine (Sigma) according to prevl- 
ously described procedures [23,24]. Silica gel 60 TLC plates were from 
Merck (Darmstadt, Germany) All solvents and other reagents ob- 
tamed from Merck or SDS (Peypm. France) were of analytical grade. 
RPM1 1640 medium. peniclllm. streptomycm, L-glutamine. trypsin- 
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EDTA and fetal calf serum were from Gibco BRL (Cergy-Pontoise. 
France). The serum substitute, Ultroser HY was from IBF (Ville- 
neuve-la-Garenne, France). 
2.2. Cell cultures 
Long-term human lymphoid cell hnes were established by Epstein- 
Barr virus-transformation of peripheral blood B lymphocytes [25.26] 
from normal individuals and from patients affected with Niemann- 
Pick disease Type A (lines ElG and MS-325) and Farber disease (lines 
Moz and GM 5748). Human skin fibroblasts derived from normal 
individuals and from patients affected with Niemann-Pick disease 
Type A (line GM 370) and Farber disease (lines Fra and GM 5752). 
The lymphoid cell line GM 5748 and the fibroblast cell line GM 5752 
derived from the same patient with Farber disease; both leukocytes 
and fibroblasts of this patient showed undetectable acid ceramidase 
activity [27]. The cell line MS-325 was kindly provided by Drs. E.H 
Schuchman and R.J. Desnick (Division of Medical Genetics, The 
Mount Sinai Medical Center, New York), the line Fra was from Drs. 
R. Gatti and P. Durand (Istituto G. Gaslini. Genova. Italy), the line 
Moz from Dr. J.M. Richardet (Hopital Trousseau, Paris. France) and 
the GM 370, GM 5748 and GM 5752 lines were from the NIGMS 
Human Genetic Mutant Cell Repository (Camden, NJ). Identical 
culture conditions were used for lymphoid cells and fibroblasts. The 
cells were routmely grown in a humidified 5% CO, atmosphere at 
37°C in RPM1 1640 medium containing L-glutamine (2 mmol/l), pen- 
icillin (100 U/ml). streptomycm (lOOpg/ml) and heat-inactivated fetal 
calf serum (10%) as previously reported [26]. Cultured skin fibroblasts 
were used Just after reaching confluency. 
2.3. Prepuration of serum-enriched medium contarnrng [3H]sphm- 
gomyhn 
A chloroform/methanol (2:l v/v) solution of the radioactive SPM 
was evaporated under nitrogen. The residue was dissolved m a small 
volume of absolute ethanol and mtxed with sterile culture medium 
contaming 10% fetal calf serum [26]. This medium was warmed at 
37°C for about 15 min. The final concentration of radiolabelled SPM 
in the incubation medium averaged 4 x lo6 dpm/ml (i.e. 4.5 nmol/ml) 
and that of ethanol did not exceed 0.7% (by vol.). 
2.4 Preparation of LDL-ussociated [‘H]sphingomyelrn 
This method will be described in detail elsewhere (T Levade. D. 
Graber and R. Salvayre, manuscript in preparation). Briefly. an etha- 
nohc solution of [3H]SPM (about 700 x IO6 dpm) was mixed with 10 
ml of filtered pooled fresh human sera and incubated overnight at 
37°C. The subsequently labelled LDL were isolated by discontmuous 
density gradient ultracentrifugation in a vertical rotor [28]. extensively 
dialyzed and filtered through a 0.2 pm pore diameter membrane filter. 
The mcorporation of SPM into LDL averaged 12,500 dpm/pg apo- 
lipoprotein B. More than 95% of the radioactive SPM was associated 
with LDL as measured after agarose gel (Hydragel Sebia) electropho- 
resis. The physical and biological properties of these [‘HISPM-labelled 
LDL were similar to their native counterparts (T. Levade. D. Graber 
and R. Salvayre, in preparation). 
2.5. Incubation of intact ceils with [‘H]sphingomyelm 
Before the experiments were initiated, the cells were grown for 2-3 
days m RPM1 1640 medium containing L-glutamine, antibiotics and 
2% Ultroser HY. a serum substitute. Cells were then incubated at 
37°C either with fetal calf serum-enriched medium containing 
[3H]SPM (data not shown) or with medium containing 2% Ultroser 
HY and LDL-associated [‘H]SPM (the final concentration of LDL in 
the incubation medium approximated 50 pg apolipoprotein B/ml). 
There was no difference in the [3H]SPM uptake levels between normal 
and Farber cells. After either 3 or 24 h pulse, the medium was removed 
and the cells were washed twice (lymphoid cells were sedimented by 
slow-speed centrtfugation) m RPM1 medium containing 10% fetal calf 
serum. Fresh medium supplemented with 10% fetal calf serum was 
added to the cells and incubation continued for the indicated times 
(from 0 to 96 h). At the end of incubation, cells were washed three 
times with PBS containing bovine serum albumin (2 mg/ml) and then 
twice with PBS alone [26]. The cell pellets were stored at -20°C. 
2.6. Liprd extructlon and analyses 
Cell pellets were suspended in 0.5 ml distilled water and sonicated 
for 3 x 15 s (Somprep MSE somcator). An ahquot was taken for 
protein determmation [29], another for estimating the total cell-associ- 
ated radioactivity by liquid scmtillation counting (Packard Tricarb 
4530 spectrometer), and the remaining was extracted with 2.5 ml of 
chloroform/methanol (2:l v/v). vortex mixed and centrifuged at 
1000 x g for 15 mm [30]. The lower phase was evaporated under 
nitrogen and the lipids were resolved by analytical TLC developed in 
chloroform/methanol/water (100:42:6 v/v) up to the 2/3 of the plate 
and then in chloroform/methanol/acetic acid (96:4:1 v/v). The dtstribu- 
tion of the radioactivity on the plate was analyzed using a Berthold 
LB 2832 radiochromatoscan. Unlabelled and radioactive lipid stan- 
dards were used to identify the various [3H]SPM metabolic products 
3. RESULTS AND DISCUSSION 
Previous studies have examined on intact Farber fi- 
broblasts the metabolic fate of the ceramide itself [3 1,321 
or the ceramide derived from sulfatide hydrolysis [33]. 
However, the effective residual activity of lysosomal 
ceramidase has not been determined because no pulse- 
chase experiments were performed [33] or because the 
ceramide was probably degraded by non-lysosomal cer- 
amidase(s) due to deficient targetting of the lipid sub- 
strate to the lysosomes [31,32]. In one of these studies 
[32], the turnover of a ceramide incorporated into re- 
constituted LDL was followed by a pulse-chase experi- 
ment. But, presumably due to abnormal processing of 
the delipidated and relipidated lipoprotein, even normal 
cells could not degrade the ceramide during the 24 h 
pulse and to a small extent (30%) during the chase pe- 
riod. We therefore undertook the re-estimation of the 
lysosomal ceramidase activity in Farber cells. As LDL 
are delivered to lysosomes [34], they represent a useful 
vehicle for transport of lipids to these organelles. Since 
ceramide is not a normal component of LDL, we de- 
cided to follow the metabolism of SPM, the natural 
sphingolipid constituent of lipoproteins which is also 
the immediate precursor of ceramide. 
The first approach we used was to introduce directly 
radiolabelled SPM into a culture medium containing 
fetal calf serum. This mode of administration has indeed 
been shown to essentially result in LDL receptor-medi- 
ated endocytosis and lysosomal hydrolysis of SPM [26]. 
Unexpectedly, two different lymphoid cell lines and two 
different fibroblast cell lines from Farber disease pa- 
tients showed a considerable ability to metabolize the 
exogenously supplied sphingolipid (data not shown). 
Although the levels of undegraded ceramide (expressed 
as percentage of the total SPM metabolites) in Farber 
cells remained higher than in normal cells. they repre- 
sented less than 20-30% after 4 days chase. We hypo- 
thesized that this high residual ceramidase activity in 
Farber cells might be related to the participation of non- 
lysosomal ceramidase(s) because of incomplete target- 
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ting of the SPM to the lysosomes. This was supported 
by the finding that, during the same chase period, about 
lo-15% of the SPM administered in the presence of 
serum was hydrolyzed in cells from patients with 
Niemann-Pick disease Type A, which are completely 
deficient in lysosomal sphingomyelinase activity [26] 
(data not shown). Therefore, the procedure of admini- 
stration of SPM was modified in order to avoid non- 
lysosomal degradation. 
specifically hydrolyzed into the lysosomal compartment 
was ascertained by the virtual absence of degradation 
in cells derived from the most severe form of Niemann- 
Pick disease, i.e. Type A (see inset of Fig. 2). 
We recently developed a convenient method to stably 
associate radiolabelled SPM to purified human LDL 
and showed that this SPM was selectively internalized 
through the LDL receptor-mediated pathway and proc- 
essed into the lysosomes of intact cells (T. Levade, D. 
Graber and R. Salvayre, in preparation). Hence. we 
investigated the metabolism of LDL-associated 
[3H]SPM in Farber cells. The fact that this SPM was 
As illustrated in Fig. 1, normal lymphoid cells pulsed 
with LDL-associated [3H]SPM exhibited a very active 
metabolism of the ceramide produced via SPM hydrol- 
ysis. Radiolabelled glycerophospholipids, neutral lipids 
and sphingolipids including SPM and glycolipids were 
found on TLC and resulted from the cellular re-utiliza- 
tion of the fatty acid and sphingoid base liberated by 
ceramidase. Although the absolute amounts of radiola- 
belled ceramide in Farber lymphoid cells remained 
higher than in normal cells (Fig. 1. middle), they de- 
creased after 24 h incubation. This was accompanied by 
a clear increase in the amounts of the various metabolic 
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Ftg. 1. Incorporatton of radioactivity mto dtfferent lipids of cultured normal and Farber lymphotd cells pulsed wtth LDL-assoctated [ZH]SPM. 
Lymphoid cell lines dertved from 5 different normal subjects and from a pattent with Farber disease (GM 5748) were incubated m medmm 
supplemented wtth 2% Ultroser HY and LDL-associated [‘H]SPM (- 53 pug apolipoprotem B/ml; - 12500 dpm/pg). After either 3 h (--; upper 
panel) or 24 h (- - -; lower panel) pulse, cells were sedimented, washed twrce with medmm contaming 10% fetal calf serum and chased in thts medtum 
for the indicated times The cell-associated radtolabelled liptds (SPM. ceramide and other metabolites) were extracted, separated by TLC and 
quantified as descrtbed m Matertals and Methods The data correspond to the mean f SD. of up to 4 and 8 separate expertments for normal and 
Farber cells. respecttvely and are expressed as pmol/mg cell protem. 
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Fig. 2. Xme course of ceramide degradation m normal and Farber cultured lymphoid cells pulsed with LDL-associated [‘HISPM. Lymphoid cell 
lines derived from 5 different normal subjects (o), a patient with Farber disease (GM 5748, W) and a patient with Niemann-Pick disease Type A 
(A) were incubated exactly as described in the legend to Fig. I. After 3 h (-) or 24 h (- - -) pulse, cells were chased and processed as indicated 
in the legend to Fig. 1. The amount of undegraded ceramide is expressed as the percentage of the total radiolabelled lipids mmus SPM [33]. The 
inset shows the time course of degradation of [‘H]SPM (expressed as percentage of total cell-associated lipids) in the different cell lines. 
was also calculated by the ratio of undegraded ceramide 
to the total lipid products of SPM hydrolysis, that is by 
subtracting the SPM in order to consider the ceramide 
as the starting substrate [33]. After a 3 h pulse, lymphoid 
cells from Farber disease exhibited a ceramide level of 
about 92% of the total SPM metabolic products (Fig. 
2). This value further increased to 97% during the fol- 
lowing 3-6 h of chase due to the continuation of SPM 
hydrolysis (see Fig. 1, left). After the rate of SPM degra- 
dation levelled off, i.e. after 9-24 h (see also Fig. 2, 
inset), a continuous decrease of ceramide was noted in 
Farber cells. When cells were pulsed for 24 h, a similar 
time course of degradation was observed. Thus, after a 
5 days incubation, undegraded ceramide in Farber lym- 
phoid cells represented only 34% of the SPM meta- 
bolites (Fig. 2). 
As Farber disease is characterized by a striking in- 
volvement of subcutaneous tissues [22], the metabolism 
of LDL-associated [3H]SPM was also examined in cul- 
tured skin fibroblasts. Fig. 3 shows that fibroblasts ex- 
hibited almost the same metabolic pattern as lymphoid 
cells. After a short increase, the absolute amounts of 
radiolabelled ceramide in Farber fibroblasts showed a 
progressive decrease (Fig. 3, middle) while its metabolic 
products increased (Fig. 3, right). Fig. 4 shows that, 
under conditions of selective lysosomal hydrolysis of 
SPM (see the pattern for Niemann-Pick disease cells in 
the inset of Fig. 4), the kinetics of ceramide degradation 
in Farber fibroblasts were superimposable on those ob- 
tained in Farber lymphoid cells. 
From the decay curves of the ceramide derived from 
LDL-associated [3H]SPM, we calculated the approxi- 
mate half-times and initial velocities of lysosomal cer- 
amide degradation. These parameters still remain un- 
derestimated since both SPM and ceramide degradation 
occurred very soon after uptake of the LDL-associated 
substrate (half of the receptor-bound LDL particles are 
internalized every 3 min [34]). Nevertheless, as shown 
in Table I, the half-time of ceramide in Farber cells was 
27-39 times more elevated than in normal cells. How- 
ever, the ceramidase activity in Farber cells was not 
completely deficient since a residual activity of about 
4% was found. These calculations were done for cells 
derived from the same Farber patient. According to our 
results when using serum-enriched medium containing 
SPM (data not shown), one can reasonably speculate 
that the residual ceramidase activity is even higher in the 
two other Farber patients we studied. 
The effective levels of in situ lysosomal ceramidase 
activity in Farber disease are in the same range as those 
found in cells from the late-onset types of other sphin- 
golipidoses, e.g. juvenile and adult GMZgangliosidoses 
[35], metachromatic leukodystrophy [35], or Niemann- 
Pick disease Type B (D. Graber, R. Salvayre and T. 
Levade. in preparation). 
Thus, our data support the conclusion that the hy- 
drolysis of ceramide by lysosomal ceramidase is not 
completely blocked in intact Farber cells. The results 
could also be interpreted by an effiux of ceramide out 
of the lysosomes and a subsequent non-lysosomal deg- 
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Fig. 3. Incorporation of radioactivity into different lipids of cultured normal and Farber fibroblasts pulsed with LDL-associated [‘H]SPM. Skin 
fibroblasts from 7 different normal subjects and a patient with Farber disease (GM 5752) were incubated with LDL-associated [3H]SPM as described 
in the legend to Fig. 1. After either 3 h (-, upper panel) or 24 h (- - -; lower panel) pulse, cells were chased and cell-associated radiolabelled lipids 
(SPM, ceramide and other metabohtes) were extracted, separated and quantified as described m Matertals and Methods. The data are expressed 
as pmok’mg cell protem and correspond to the mean + S.D of up to 9 and 3 separate xpcrtments for normal and Farber fibroblasts. respectively. 
radation. However, in contrast to short chain ceramides 
which are cell-permeable [9-121, it is not known whether 
natural, hydrophobic ceramides can get easily across a 
membrane. In addition, electron microscopy studies 
have indeed demonstrated ceramide accumulation in 
the lysosomes of cultured Farber fibroblasts overloaded 
with natural ceramides [36]. 
The high residual activity of lysosomal ceramidase in 
lymphoid cells might explain the absence or mild in- 
volvement of the bone marrow and reticuloendothelial 
system in Farber disease [22]. The involvement of sub- 
cutaneous tissues in the patients may be accounted for 
by the production of large quantities of ceramide by the 
skin [3-51 that could not be accomodated by the residual 
ceramidase activity present in fibroblasts. 
Our data also provide some indication about the pos- 
sible role of ceramide as a lipid mediator [f&12]. If 
Table I 
Approximate half-time and mittal rates of degradation of ceramide in 
intact normal and Farber cells 
Cell type Half-time Initial velocity 
(hours) (pmol/h.mg) 
Normal Farber Normal Farber 
Lymphoid cells 2.1 82.8 15.4 0.6 
Fibroblasts 2.7 73.1 95.9 34 
The half-time of ceramide was calculated from the exponential curves 
of the ceramide degradation derived from the data m Figs. 2 and 4 (for 
Farber cells, the values of ceramide concentration at 3 and 6 h were 
omitted and mean values were considered for the 3 h pulse and 24 h 
pulse experiments). The mittal velocittes were calculated based on a 
mean uptake of LDL-assocrated [%]SPM of 110 and 550 pmollmgcell 
protein for lymphoid cells and fibroblasts, respecttvely and assuming 
a 70% degradation of SPM to ceramide (see insets of Figs. 2 and 4). 
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Fig. 4. Time course of ceramtde degradation m normal and Farber cultured fibroblasts pulsed with LDL-associated [‘HISPM. Skin fibroblasts from 
7 different normal subjects (o), a patient with Farber disease (GM 5752, n ) and a patient with Niemann-Pick disease Type A (A) were incubated 
for 3 h (-) or 24 h (- - -) with LDL-associated [lH]SPM, and then chased as described in the legend to Fig. 3. The data are presented as in Fig. 2. 
ceramide is a potent second messenger, a relative in- 
crease of the ceramide levels may lead with time to 
deleterious effects on the cell functions. However, the 
presence of a still active lysosomal ceramidase in Farber 
disease as found in this study may protect from early 
fatal lesions. Alternatively, the ceramide found in Far- 
ber cells or tissues could be without effect on its cellular 
targets because it remains localized in the lysosomes. 
This would implicate that the acid, lysosomal sphin- 
gomyelinase is not the enzymatic system which has been 
proposed by some authors [37,38] to generate ceramide 
molecules as bioeffectors. Finally, it cannot yet be com- 
pletely excluded that ceramide may, in part, escape in- 
tralysosomal degradation and leave the lysosomes. 
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